Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras School of Health Sciences, University Campus, Patras, GR-26504, Greece.
College of Medicine and Health Sciences, Department of Genetics and Genomics, United Arab Emirates University, Al-Ain, Abu Dhabi, United Arab Emirates.
Hum Genomics. 2024 Jul 19;18(1):82. doi: 10.1186/s40246-024-00648-y.
Pharmacogenomics (PGx) constitutes an important part of personalized medicine and has several clinical applications. PGx role in clinical practice is known, however, it has not been widely adopted yet. In this study, we aim to investigate the perspectives of Greek physicians regarding the implementation of PGx testing in clinical practice and the key issues associated with it.
Fourteen interviews were conducted with physicians of various specialties for which PGx applications are available. A semi-structured interview guide was utilized based on the Consolidated Framework for Implementation Research (CFIR) context and the Diffusion of Innovation model. Transcripts were coded independently and compared by two members of the research team. Descriptive statistics were generated using Microsoft Excel.
Six main themes emerged: awareness and use of PGx testing; source of information; key stakeholders of the PGx supply chain, their interactions and change agents; clinical benefit and significance of PGx testing; barriers and lack of reimbursement; and recommendations to boost the PGx adoption rate. Most respondents were aware of PGx applications, but only three had already recommended PGx testing. Peer-reviewed journals along with clinical guidelines were regarded as the most used source of information while stakeholders of the PGx supply chain were discussed. PGx was considered that promote patient-centered care, enhance medication clinical effectiveness, decrease the risk of side effects, and reduce healthcare costs. Lack of reimbursement, scarcity of resources, and high PGx cost were the foremost barriers affecting PGx adoption.
It was concluded that if case PGx testing is reimbursed and physicians' training is reinforced, PGx implementation will be boosted and improved shortly.
药物基因组学（PGx）是个性化医学的重要组成部分，具有多种临床应用。尽管 PGx 在临床实践中的作用已为人所知，但尚未得到广泛采用。在这项研究中，我们旨在调查希腊医生对在临床实践中实施 PGx 检测的看法，以及与之相关的关键问题。
对具有 PGx 应用的各种专业的 14 名医生进行了 14 次访谈。根据综合实施研究框架（CFIR）背景和创新扩散模型，使用半结构化访谈指南。两名研究团队成员独立对记录进行编码并进行比较。使用 Microsoft Excel 生成描述性统计数据。
出现了六个主要主题：对 PGx 检测的认识和使用；信息来源；PGx 供应链的主要利益相关者、他们的互动和变革推动者；PGx 检测的临床益处和意义；障碍和缺乏报销；以及提高 PGx 采用率的建议。大多数受访者都知道 PGx 的应用，但只有三人曾推荐过 PGx 检测。同行评议的期刊以及临床指南被认为是最常用的信息来源，同时还讨论了 PGx 供应链的利益相关者。PGx 被认为可以促进以患者为中心的护理，提高药物治疗的临床效果，降低副作用风险，并降低医疗保健成本。缺乏报销、资源稀缺和高 PGx 成本是影响 PGx 采用的首要障碍。
如果对 PGx 检测进行报销并且加强医生的培训，PGx 的实施将得到促进和改善。
